Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How to induce remission in primary systemic vasculitis.

David Jayne1

  • 1Nephrology and Vasculitis, Box 118, Renal Unit, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK. dj106@cam.ac.uk

Best Practice & Research. Clinical Rheumatology
|April 29, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-stapling versus double-stapling technique for rectal anastomosis-meta-analysis.

BJS open·2026
Same author

Hypogammaglobulinaemia in patients with ANCA-associated vasculitis treated with rituximab.

Frontiers in medicine·2026
Same author

Update on therapeutic approaches in ANCA-associated vasculitis.

EULAR rheumatology open·2026
Same author

Long-term risk of malignancies in ANCA-associated vasculitis.

EULAR rheumatology open·2026
Same author

Radiological staging clinical decision support model for rectal cancer lymph node metastasis detection on MRI.

BMC cancer·2026
Same author

Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis.

Clinical pharmacology and therapeutics·2026

Systemic vasculitis is manageable with combination therapy, achieving remission in most patients. Research focuses on reducing treatment toxicity and improving long-term outcomes with new therapies.

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Systemic vasculitis is a treatable but chronic autoimmune condition.
  • Current standard therapy involves corticosteroids and immune suppressives, achieving high remission rates.
  • Challenges include treatment toxicity, remission quality, and relapse prevention.

Purpose of the Study:

  • To review current treatment strategies for systemic vasculitis.
  • To discuss ongoing challenges in managing the disease.
  • To highlight emerging therapies and future research directions.

Main Methods:

  • Review of existing literature and randomized controlled trials.
  • Analysis of current therapeutic regimens and their outcomes.
  • Discussion of novel immunosuppressive agents and biologics.

Related Experiment Videos

Main Results:

  • Combination therapy with corticosteroids and immune suppressives induces remission in ~90% of patients.
  • Cyclophosphamide is a highly effective immunosuppressive, with toxicity mitigation strategies.
  • Newer agents targeting cytokine blockade and lymphocyte depletion are emerging.

Conclusions:

  • Optimizing induction regimens based on patient subgroups is crucial.
  • Minimizing therapeutic toxicity, especially in elderly patients, remains a priority.
  • Integrating novel therapies to improve long-term outcomes is the key challenge in clinical vasculitis research.